|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-IOR-15005953 |
|
Date of registration:
|
2015-01-11 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The effects of corticosteroid treatment on asymptomatic sarcoidosis
|
|
Scientific title:
|
The effects of corticosteroid treatment on asymptomatic sarcoidosis |
|
Date of first enrolment:
|
2012-01-01 |
|
Target sample size:
|
Corticosteroid-treated group :64;Placebo:63; |
|
Recruitment status: |
Completed |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=10412 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
Other
|
|
|
Contacts
|
|
Name:
|
Linling Cheng
|
|
Address:
|
Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital, Guangzhou Medical University
|
|
Telephone:
|
+86 13902233092 |
|
Email:
|
linling@gird.cn |
|
Affiliation:
|
|
|
|
Name:
|
Linling Cheng
|
|
Address:
|
Guangzhou Institute of Respiratory Diseases, the First Affiliated Hospital, Guangzhou Medical University
|
|
Telephone:
|
+86 13902233092 |
|
Email:
|
linling@gird.cn |
|
Affiliation:
|
the First Affiliated Hospital, Guangzhou Medical University |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: The inclusion criteria were:
(1) sarcoidosis confirmed by pathological results of lung tissues;
(2) no significant cough, shortness of breath, and other symptoms presenting within the last month;
(3) normal lung functions including FEV1, FEV1/FVC, FVC and diffusing capacity;
(4) no disease involvement of external organs (including heart) other than chest.
Exclusion criteria: (1) pulmonary tuberculosis, lymphoma or other pulmonary diseases;
(2) inhaled or oral corticosteroid treatment within the last three months.
Age minimum:
18
Age maximum:
76
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Sarcoidosis
|
|
Intervention(s)
|
|
Corticosteroid-treated group :prednisolone ;Placebo:Placebo;
|
|
Primary Outcome(s)
|
|
newly developed clinical symptom;Lung functions (Including FEV1, FVC and DLCO);the yield of non-caseating granuloma in bronchial mucosa;CD4/CD8 ratio in bronchoalveolar lavage (BAL) fluid;
|
|
Secondary Outcome(s)
|
|
Adverse events;
|
|
Source(s) of Monetary Support
|
|
Guangdong Nature Science Funding
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|